| BLDR |
Report |
Sales |
IN-LINE |
pred ~$3.90B vs. cons $3.920B |
MEDIUM |
| BLDR |
Report |
Adjusted EBITDA |
MISS |
pred ~$325M vs. cons $331.6M |
MEDIUM |
| BLDR |
Report |
Adjusted diluted EPS |
MISS |
pred ~$1.18 vs. cons $1.231 |
MEDIUM |
| BLDR |
Guide |
Q3 2026 sales |
LOWER |
guide ~$3.95B vs. cons $4.019B |
LOW |
| BLDR |
Guide |
Q3 2026 adjusted EBITDA |
LOWER |
guide ~$370M vs. cons $381.3M |
LOW |
| BLDR |
Guide |
FY26 sales |
UNCHANGED |
guide $14.6B-$15.6B vs. cons $14.768B |
MEDIUM |
| BLDR |
Guide |
FY26 adjusted EBITDA |
UNCHANGED |
guide $1.1B-$1.5B vs. cons $1.202B |
MEDIUM |
| BLDR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
LOW |
| BLDR |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — lower Q3 estimates should reinforce the initial move |
LOW |